Free Daily Biotech Industry Newsletter
Get the latest on Biotech & Pharma Deals, Clinical Trials, FDA Decisions, and Key Regulatory Issues sent straight to your Inbox. Join over 148,000 biotech professionals who subscribe to FierceBiotech for FREE!
Shares of BioSante ($BPAX) shot up more than 20% this morning after the developer heralded data showing improved survival rates in an early trial of GVAX for pancreatic cancer. The data is from a trial that recruited 30 patients. Story
| Download Today | Sponsored by: BaxterWhile the development of an aqueous solution formulation may be preferred over a lyophilized product, it is useful to initially pursue a dual path and develop drug product formulations for both a sterile solution and a freeze-dried solid presentation. Learn More Today!
FierceBiotech monitors biotech & pharma deals, FDA decisions, clinical trials, and more. Join more than 148,000 biotech industry leaders who subscribe to our free daily email. Click here to get your free weekly email briefing today!